Diagnosis

Malignant hyperthermia

A rare life threatning hyperthermia assosiated with hypermatabolic syndrome after exposure to anestethic agents.

Etiology

Cause [rrv][fmm]

Pathophysiology [rrv]

  1. Impaired reuptake of calcium by sarcoplasmic reticulum in muscles

  2. Uncontrolled lasting muscle activation

  3. ATP depletion --> compromised muscle membrane

  4. Severe hyperthermia (core temperature > 44°C) may occur

  5. Increased oxygen consumption, carbon dioxide production, worsening metabolic acidosis, heart failure, bowel ischemia, compartment syndrome, myocyte death, rhabdomyolysis myoglobinuria, acute renal failure, life-threatening hyperkalemia and disseminated intravascular coagulation

Complications [rrv]

Epidemiology

Incidence per 100.000 [fmm]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Arrhythmia, Dark urine, Fever, Hyperthermia, Muscle hypertonia, Tachycardia, Tachypnea

Clinical findings

Acidosis, Elevated Creatine Kinase, Hypercapnia, Hyperkalemia, Hypoxemia

Anamneses

None listed.

Approach

Treatment

  1. Immediate discontinuation of trigger agents (inhalation agents, succinylcholine) [fmm]

  2. Hyperventilation to lower ETCO2

  3. Dantrolene initial dose 2.5 mg/kg repeated pro re nata, upper limit 10 mg/kg, titrate to tachycardia and hypercarbia, then 1 mg/kg every 4–8 hours for 24–48 hours

  4. Cooling by all routes available:

    • Nasogastric lavage

    • Ice Packs to groin, axilla, and neck

  5. Treat hyperkalemia and arrhythmias (do not use calcium channel blockers)

  6. Insure urine output of 2 ml/kg/hour with mannitol, furosemide, and fluids as needed

  7. Monitor blood gases, electrolytes, creatine kinase, blood and urine for myoglobin, coagulation profile

  8. Evaluate need for invasive monitoring and continued mechanical ventilation

  9. Observe patient in Intensive Care Unit for at least 36 hours

Differential diagnoses

Becker muscular dystrophy, Cocaine toxicity, Cystinosis, Diabetic ketoacidosis, Drug side effects, Duchenne muscular dystrophy, Febrile seizure, Heatstroke, Hyperthyroidism, Muscular dystrophy, Neuroleptic malignant syndrome, Pheochromocytoma, Rhabdomyolysis, Sepsis, Thyrotoxicosis


References

[1] Watt S, McAllister RK. Malignant Hyperthermia. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430828/

[2] Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007 Apr 24;2:21.

[3] Kim DC. Malignant hyperthermia. Korean J Anesthesiol. 2012 Nov;63(5):391-401.

[4] https://emedicine.medscape.com/article/2231150

[5] Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg. 2009 Oct;109(4):1162-6.

[6] Sumitani M, Uchida K, Yasunaga H, Horiguchi H, Kusakabe Y, Matsuda S, Yamada Y. Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database. Anesthesiology. 2011 Jan;114(1):84-90.

[7] Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005 Jun 15;293(23):2918-24.

[8] Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015 Aug 4;10:93.

[9] Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, McGrady E. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021 May;76(5):655-664.

Scroll to top